Provided by Tiger Fintech (Singapore) Pte. Ltd.

Precigen

3.19
+1.3472.43%
Volume:147.27M
Turnover:449.70M
Market Cap:950.53M
PE:-7.43
High:3.49
Open:2.60
Low:2.51
Close:1.85
52wk High:3.49
52wk Low:0.6513
Shares:297.97M
Float Shares:149.07M
Volume Ratio:85.65
T/O Rate:98.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4294
EPS(LYR):-0.4715
ROE:-668.03%
ROA:-67.44%
PB:-25.84
PE(LYR):-6.77

Loading ...

Crude Oil Down 1%; US Retail Sales Rise 0.5% In July

Benzinga
·
42 mins ago

Precigen Up Nearly 67%, On Pace For Largest Percent Increase Since June 2020 -- Data Talk

Dow Jones
·
Yesterday

Precigen Shares up 41.6% After US FDA Approves Its Immunotherapy for Rare Respiratory Disease

THOMSON REUTERS
·
Yesterday

Morning Movers: Precigen surges following full FDA approval of Papzimeos

TIPRANKS
·
Yesterday

Precigen Raised to Neutral From Underweight by JP Morgan

Dow Jones
·
Yesterday

AquaBounty Technologies Announces Resignation of General Counsel Angela Olsen

Reuters
·
Yesterday

HC Wainwright Adjusts Price Target on Precigen to $8.50 From $6, Maintains Buy Rating

MT Newswires Live
·
Yesterday

Precigen Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Yesterday

Precigen, Inc. : H.c. Wainwright Raises Target Price to $8.5 From $6

THOMSON REUTERS
·
Yesterday

JPMorgan Upgrades Precigen to Neutral From Underweight

MT Newswires Live
·
Yesterday

Precigen Shares Surge More Than Double After US FDA Approves Its Immunotherapy for Rare Respiratory Disease, Last up 102% Premarket

THOMSON REUTERS
·
Yesterday

BRIEF-Precigen Announces Full FDA Approval Of Papzimeos

Reuters
·
Yesterday

US FDA approves Precigen's immunotherapy for rare respiratory disease

Reuters
·
Yesterday

Precigen Inc. Secures FDA Approval for PAPZIMEOS, Offering New Hope to Adult RRP Patients

Reuters
·
Yesterday

Precigen Announces Full FDA Approval of Papzimeos (Zopapogene Imadenovec-Drba), the First and Only Approved Therapy for the Treatment of Adults With Recurrent Respiratory Papillomatosis

THOMSON REUTERS
·
Yesterday

FDA: on Aug 14, FDA Approved First Immunotherapy for Recurrent Respiratory Papillomatosis

THOMSON REUTERS
·
Yesterday

FDA approves Precigen immunotherapy for respiratory papillomatosis

TIPRANKS
·
Yesterday

U.S. RESEARCH ROUNDUP-Applied Materials, Precigen, Transdigm Group

Reuters
·
Yesterday

Precigen Gets FDA Approval of Respiratory-Tumor Treatment

Dow Jones
·
Yesterday

Precigen trading halted, news pending

TIPRANKS
·
Yesterday